Novocure Inc. shares plunged following an announcement that the Phase 3 TRIDENT study failed to meet its prespecified primary endpoint. In pre-open trading the stock declined 17.5% after topline results indicated no statistically significant overall survival advantage for patients who began Tumor Treating Fields - TTFields - at the time of chemoradiation compared with those who started TTFields during the maintenance phase.
The trial enrolled 981 patients and compared two approaches to initiating the device-based therapy. Median overall survival was effectively unchanged between the arms at 17.7 months versus 17.5 months. The reported hazard ratio was 0.953 and the p-value was 0.519, indicating the observed difference did not reach statistical significance.
Investors had been looking to TRIDENT as a near-term growth driver for the company. Management had highlighted the trial as the next major milestone in its glioblastoma program during the Q1 2026 earnings call, with top-line data expected in the second quarter. That framing contributed to the stock advancing near its 52-week high of $18.92 ahead of the readout.
The negative result removes the prospect of expanding the approved use of Optune Gio into the chemoradiation phase of care. Market participants had viewed such an expansion as a way to extend the duration of therapy delivered per patient, and the failure to demonstrate a survival benefit forecloses that potential commercial pathway.
Broader market conditions added to the downward pressure on shares. Major U.S. equity benchmarks were lower - the S&P 500 was down 1.2%, the Nasdaq fell 1.3% and the Dow Jones Industrial Average declined 1.0% - as investors parsed the Federal Reserve's most recent meeting. New Fed Chair Kevin Warsh conveyed a more hawkish tone, and the Fed's dot plot showed a majority of officials open to at least one rate increase later in 2026. That shift in monetary policy expectations has weighed on growth-oriented and biotechnology stocks across the market.
Combined, the high-profile clinical setback that eliminates a key pipeline catalyst and a risk-off macro environment caused Novocure shares to drop sharply in pre-market trading. The move erased a large portion of the stock's recovery from its 52-week low of $9.82 and pushed the price well below the prior session's close of $17.85.
What happened
- The Phase 3 TRIDENT trial did not show a statistically significant overall survival benefit for concurrent TTFields with chemoradiation versus TTFields started during maintenance.
- Median survival was 17.7 months versus 17.5 months; hazard ratio 0.953; p-value 0.519.
- Shares fell 17.5% in pre-market trading, reversing much of the earlier run-up toward a 52-week high.
Market context
- Major U.S. indices were lower amid expectations of tighter monetary policy after comments from the Federal Reserve and a hawkish dot plot.
- Biotech and growth names experienced broader weakness as investors reacted to the macro signal.
Implication for Novocure
The trial result blocks the pathway management had highlighted for potentially expanding Optune Gio use into an earlier phase of treatment, a scenario that had been expected to increase the duration of therapy per patient if approved.